Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C6H12N2O4S2 |
Molecular Weight | 240.3 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CSSC[C@H](N)C(O)=O)C(O)=O
InChI
InChIKey=LEVWYRKDKASIDU-IMJSIDKUSA-N
InChI=1S/C6H12N2O4S2/c7-3(5(9)10)1-13-14-2-4(8)6(11)12/h3-4H,1-2,7-8H2,(H,9,10)(H,11,12)/t3-,4-/m0/s1
DescriptionSources: https://www.drugbank.ca/drugs/DB00138Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7276953 | https://www.ncbi.nlm.nih.gov/pubmed/27306219 | https://www.ncbi.nlm.nih.gov/pubmed/28297659
Sources: https://www.drugbank.ca/drugs/DB00138
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7276953 | https://www.ncbi.nlm.nih.gov/pubmed/27306219 | https://www.ncbi.nlm.nih.gov/pubmed/28297659
Cystine is the oxidized dimer form of the amino acid cysteine. Cystine serves two biological functions, a site of redox reactions and a mechanical linkage that allows proteins to retain their 3-dimensional structure. It is common in many foods such as eggs, meat, dairy products, and whole grains as well as skin, horns and hair. Human hair and skin contain approximately 10–14% cystine by mass. Cysteine supplements are sometimes marketed as anti-aging products with claims of improved skin elasticity. Cysteine is more easily absorbed by the body than cystine, so most supplements contain cysteine rather than cystine. N-acetyl-cysteine (NAC) is better absorbed than other cysteine or cystine supplements.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1075149 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28070112 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | Unknown Approved UseUnknown |
|||
Secondary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
An algorithm for mapping positively selected members of quasispecies-type viruses. | 2001 |
|
Histological and histochemical observations in the stomach of the Senegal sole, Solea senegalensis. | 2001 Apr |
|
Homologues of archaeal rhodopsins in plants, animals and fungi: structural and functional predications for a putative fungal chaperone protein. | 2001 Apr 2 |
|
[Toxic epidermal necrolysis (drug-induced Lyell's syndrome). 2. Treatment]. | 2001 Feb 16 |
|
The role of disulfide bridge in the folding and stability of the recombinant human prion protein. | 2001 Jan 26 |
|
Hyperglycemia in diabetic rats reduces the glutathione content in the aortic tissue. | 2001 Jul 20 |
|
Cystinuria in the dog: clinical studies during 14 years of medical treatment. | 2001 Jul-Aug |
|
Increased plasma tryptophan in HIV-infected patients treated with pharmacologic doses of nicotinamide. | 2001 Jul-Aug |
|
Estimation of the total sulfur amino acid requirement and the effect of betaine in diets deficient in total sulfur amino acids for the weanling pig. | 2001 Jun |
|
How does hexachlorobenzene treatment affect liver uroporphyrinogen decarboxylase? | 2001 Jun |
|
Electroanalytical exploitation of quinone-thiol interactions: application to the selective determination of cysteine. | 2001 Mar |
|
Three-dimensional structure of human follicle-stimulating hormone. | 2001 Mar |
|
Effect of oxygen on induction of the cystine transporter by bacterial lipopolysaccharide in mouse peritoneal macrophages. | 2001 Mar 30 |
|
Human cystinuria-related transporter: localization and functional characterization. | 2001 May |
|
Design of Gram-negative selective antimicrobial peptides. | 2001 May 15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27306219
The subjects in the C/T group were orally administered an amino acid supplement, which contained 700 mg cystine and 280 mg theanine (total weight, 1.7 g; Ajinomoto, Tokyo, Japan), once a day starting 1 week before and ending at the same time as the administration of S-1 (a total of 35 days)
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28297659
200,000 hTERT-HME cell were plated in 6-well plates and switched to cystine-deprived media for 12 hr prior to FACS analysis. CMDCFDA and C11-BODIPY581/591 (Molecular Probes; Thermo Fisher) were used to detect total and lipid ROS, respectively. Following deprivation of cystine for 12 hr, cells were washed with PBS, loaded with either CMDCFDA (10 mM) or C11 BODIPY (2 mM) in DPBS for 30 min, trypsinized with 0.25% Trypsin-EDTA, resuspended inPBSwith1%FBS, and analyzed using an AttuneNxT flow cytometer (Thermo Fisher). Dyes were excited using a blue 488-nm laser, and emission was recorded on BL1 (530/30) for a minimum of 5,000 cells per sample.
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
27027-2
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
22687-8
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
13371-0
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
12469-3
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
DSLD |
2409 (Number of products:212)
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
34278-2
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
DSLD |
76 (Number of products:12)
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
2180-8
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
NCI_THESAURUS |
C29596
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
26843-3
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
25894-7
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
32169-5
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
2179-0
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
14686-0
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
33872-3
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
10969-4
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
16709-8
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
13966-7
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
44312-7
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
53080-8
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
27350-8
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
21056-7
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
2175-8
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
32237-0
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
32238-8
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
30065-7
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
32138-0
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
2177-4
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
9644-6
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
CFR |
21 CFR 172.320
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
56677-8
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
16711-4
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
22728-0
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
2178-2
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
26962-1
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
13725-7
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
2176-6
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
22672-0
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
22653-0
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
||
|
LOINC |
13394-2
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
D003553
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
PRIMARY | |||
|
1161586
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
PRIMARY | |||
|
DB00138
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
PRIMARY | |||
|
SUB01541MIG
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
PRIMARY | |||
|
DTXSID2046418
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
PRIMARY | |||
|
CYSTINE
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
PRIMARY | |||
|
4130
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
PRIMARY | |||
|
13203
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
PRIMARY | |||
|
m4049
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
PRIMARY | Merck Index | ||
|
16283
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
PRIMARY | |||
|
3036
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
PRIMARY | RxNorm | ||
|
100000091082
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
PRIMARY | |||
|
48TCX9A1VT
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
PRIMARY | |||
|
48TCX9A1VT
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
PRIMARY | |||
|
C29610
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
PRIMARY | |||
|
17376
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
PRIMARY | |||
|
67678
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
PRIMARY | |||
|
200-296-3
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
PRIMARY | |||
|
SUB41569
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
PRIMARY | |||
|
35491
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
PRIMARY | |||
|
56-89-3
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
PRIMARY | |||
|
50058
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
PRIMARY | |||
|
CHEMBL590540
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
PRIMARY | |||
|
7922
Created by
admin on Wed Apr 02 09:59:50 GMT 2025 , Edited by admin on Wed Apr 02 09:59:50 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)